Tissue Regenix Group plc
('Tissue Regenix' or the
'Company')
CellRight Technologies extends multi-year
distribution agreement with Arthrex, Inc.
Tissue Regenix (AIM: TRX), the regenerative medical
devices company, announces that its subsidiary, CellRight
Technologies, LLC ("CellRight"), has amended and extended its
long-term, multi-year distribution agreement with Arthrex, Inc.
("Arthrex"), a premier innovator of orthopaedic surgical solutions.
CellRight produces industry leading verified
osteobiologics (engineered materials that promote healing of
fractures and bone defects) for use in orthopaedic, spine and foot
and ankle procedures. The multi-year commitment continues to
provide surgeons access to verified osteobiologics and advanced
surgical instrumentation and techniques to help influence better
patient outcomes. Arthrex and CellRight entered a marketing and
sales agreement in March 2017 and the amendment extends the term
until October 2029 where it will renew for additional periods.
Daniel Lee, CEO of
Tissue Regenix, commented: "The extension of our long-term distribution
agreement will continue to allow physicians and patients access to
CellRight's innovative orthobiologics through the Arthrex network.
Patient outcomes are positively impacted by orthobiologic products
together with the advanced technologies and training from Arthrex.
This shared vision is at the core of this strategic
partnership."
For more
information, please contact:
|
Tissue Regenix Group
plc
|
|
|
Daniel Lee, Chief Executive Officer
David Cocke, Chief Financial Officer
|
via Walbrook PR
|
|
Cavendish Capital
Markets (Nominated Adviser and Broker)
|
|
|
Geoff Nash/Giles Balleny/Edward Whiley
Nigel Birks - Life Science Specialist Sales
Harriet Ward - ECM
|
Tel: +44 (0) 20 7466
5000
|
|
Walbrook PR
(Financial PR and IR)
|
Tel: +44 (0)20 7933
8780
|
|
Alice Woodings / Lianne Applegarth
|
Tissue
Regenix@walbrookpr.com
|
About Tissue Regenix
(www.tissueregenix.com)
Tissue Regenix is a leading medical device
company in regenerative medicine. The Company's patented
decellularisation technology (dCELL®) removes DNA and other
cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold that is not rejected by the patient's
body and can be used to repair diseased or damaged body structures.
Current applications address many crucial clinical needs in sports
medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue
Regenix acquired CellRight Technologies®. This biotech company
specialises in regenerative medicine and is dedicated to developing
high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's
human tissue products may be used in spine, trauma, general
orthopaedic, dental and ophthalmological surgical
procedures.